Huntsville

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease8 trials
• Heart failure3 trials
• Type 2 diabetes3 trials
• COPD2 trials
• Obesity2 trials
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Follicular lymphoma1 trial
• High blood pressure1 trial
• Lung cancer1 trial
• Myeloproliferative neoplasms1 trial
• Type 1 diabetes1 trial
• and 1 more

Phase

• Phase 314 trials
• Phase 1/22 trials
• Phase 22 trials

Status

• Not yet recruiting5 trials
• Recruiting5 trials
• Active, not recruiting4 trials
• Completed4 trials
• Terminated2 trials

Lead sponsor

• AstraZeneca17 trials
• DalCor Pharmaceuticals1 trial
• Maze Therapeutics1 trial
• Silence Therapeutics plc1 trial

Running trials

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  NCT07784270· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

  NCT06830629· Phase 2· Maze Therapeutics· Source

  Contact: Maze Therapeutics

• Active, not recruiting

  A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

  NCT06749457· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

  NCT06087835· Phase 3· AstraZeneca· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· DalCor Pharmaceuticals· Source

  Contact: David Kallend, MBBS

• Active, not recruiting

  Study to Assess SLN124 in Patients With Polycythemia Vera

  NCT05499013· Phase 1/2· Silence Therapeutics plc· Source

• Active, not recruiting

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• Type 2 diabetes3 recruiting
• Heart failure2 recruiting
• Obesity2 recruiting
• Coronary artery disease1 recruiting
• Follicular lymphoma1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Completed

  A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

  NCT05967806· AstraZeneca· Source

• Completed

  Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

  NCT05408039· AstraZeneca· Source

• Completed

  A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

  NCT05432167· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source